Mya Soe Nwe
Skip Ribbon Commands
Skip to main content
Menu
Dr Mya Soe Nwe

Dr Nwe Mya Soe

MBBS, MMed Sc (Paediatrics), MRCPCH (UK)

Senior Staff Physician

KK Women's and Children's Hospital

Specialty: Paediatric Haematology/Oncology

Sub-specialties: Haematology-Oncology

Conditions Treated by this Doctor:
Children Cancer, Paediatric Haematology and Oncology.

Clinical Appointments

  • Senior Staff Physician Haematology/Oncology Service KK Women's and Children's HospitalKK Women's and Children's Hospital

Profile

Dr Mya Soe Nwe is a Senior Staff Physician in Haematology and Oncology Subspecialties of Paediatric Medicine at KK Women’s and Children’s Hospital.

Education

  • MRCPCH (United Kingdom) 2010
  • MMed Sc (Paediatrics) (Myanmar) 2002
  • MBBS (Myanmar) 1996

Professional Appointments and Committee Memberships

  • Clinical Lecturer, Yong Loo Lin School of Medicine
  • Clinical Teacher, Lee Kong Chian School of Medicine
  • Senior Staff Physician in Paediatric Haematology/Oncology, KK Women’s and Children’s Hospital 2022 - Present
  • Secretary, Paediatric Oncology Society, Singapore 2018 – to date
  • Member, Singapore Society of Haematology 2008- to date
  • Member, Royal College of Paediatrics and Childhealth (UK) 2010- to date
  • Treasurer, Paediatric Oncology Society, Singapore 2012-2014

Awards

  • Singapore Health Quality Service Award, Silver (2016)
  • Second Poster Prize (Patient Safety and Quality Symposium) (2014)
  • Singapore Health Quality Service Award, Silver (2012)

Research Interests

Publications

  • Novel deep intronic and missense UNC13D mutations in familial hemophagocytic lymphohistiocytosis type 3 (FHL3)
    Miriam Entesarian, Samuel C. C. Chiang, Heinrich Schlums, Marie Meeths, Mei-Yoke Chan , Soe-Nwe Mya, Shui-Yen Soh, Magnus Nordenskjöld, Jan-Inge Henter and Yenan
    British Journal of Haematology - BJH-2013-00191.R1 (11/7/2013)
  • Management of a Kaposiform haemangioendothelioma of the kidney with Kasabach-Meritt phenomenon without chemotherapy
    Mya Soe Nwe, Marc Weijie Ong, Joyce Ching Mei Lam, Kenneth Tou-En Chang, Marielle V. Fortier, Olivia Wijeweera, Ah Moy Tan, Amos Hong Pheng Loh
    Pediatric Hematology Oncology Journal, Volume 1, Issue 4, October 2016, Pages 89-92
  • Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in A Multiethnic Asian Population
    Tan VZZ, Chan NM, Ang WL, Mya SN, Chan MY and Chen CK (2021)
    Front. Pediatr. 9:639603. doi: 10.3389/fped.2021.639603
  • Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol.
    Sutiman N, Nwe MS, Ni Lai EE, Lee DK, Chan MY, Eng-Juh Yeoh A, Soh SY, Leung W, Tan AM.
    Clin Lymphoma Myeloma Leuk. 2020 Dec 1:S2152-2650(20)30658-3. doi: 10.1016/j.clml.2020.11.016.
  • A rare case of purpuric rash caused by Saprochaete clavata in a pediatric patient with acute leukemia
    Lynette Wei Yi Wee, Hua Yen Ling, Chia Yin Chong, Mya Nwe Soe, Mark Jean Aan Koh
    Paediatric Dermatology. 2019;00:1-2
  • High-Grade Primary Osteosarcoma of the Thoracic Spine Presenting as an Ivory Vertebra
    Khin YT, Peh WCG, Chang KTE and Mya SN
    International Journal of Cancer and Clinical Research 2018, 5:099, Volume 5. Issue 3

Research Trials

  • Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T cells for Relapsed Refractory B-Lineage Leukaemia (2021-2023)
  • FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered, Recurrent or Progressive Low-Grade Glioma (2021-2013)
  • Paediatric Haematopoietic Cell Transplantation and Cell Therapy in Malignant and Non Malignant Diseases (2020-2023)
  • Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial (2020-2023)
  • A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE) (2020 to 2022)
  • Comprehensive Genomic Profiling of Paediatric Brain and Solid Tumours in Singapore (2018- 2022)
  • Singapore-Malaysia Acute Lymphoblastic Leukaemia (ALL) 2010 Protocol (Ma-Spore ALL 2010) (2019-2023)
  • Singapore-Malaysia Acute Lymphoblastic Leukaemia (ALL) Treatment Protocol – A Risk-Stratified Study Using Primarily the Early Response to Therapy as the Risk Stratification Criteria, Incorporating Pharmacogenetics, Gene Expression Profiling, Proteomics and Cell Banking (Ma-Spore ALL 2003 Study) (2019-2023)